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Background: We investigated whether attenuating dipeptidyl peptidase-IV (DPP4) enzyme activity protected rat
heart from ischemia-reperfusion (IR) injury (40-min left anterior descending coronary artery ligation followed by 72
h reperfusion).
Methods and results: Adult male Fischer 344 rats (n = 24) were equally divided into sham-control (WT-SC), WT-IR,
and WT-IR-Sita (oral sitagliptin 400 mg/kg/day for 3 days) groups, whereas adult male DPP4-deficiency (DPP4D) rats
(n = 16) were equally divided into DPP4D-SC and DPP4D-IR groups. Animals were sacrificed at 72 h after reperfusion
with collection of heart specimens. Infarct area (H&E), collagen deposition (Sirius-red stain), fibrotic area (Masson's
trichrome), and fluorescent-ROS intensity (H2DCFDA-labeling myocardium) of left ventricle were significantly higher in
WT-IR than those in other groups, significantly higher in WT-IR-Sita and DPP4D-IR groups than in WT-SC and DPP4D-SC
groups (all p < 0.001), but there was no difference between the latter two groups. Protein expressions of oxidative stress
(oxidized protein), reactive oxygen species (NOX-1, NOX-2), inflammation (TNF-α, NF-κB, MMP-9, VCAM-1), apoptosis
(mitochondrial Bax, cleaved caspase-3 and PARP), myocardial damage markers (cytosolic cytochrome-C, γ-H2AX), and
number of inflammatory cells (CD14+, CD68+, CD40+ cells) showed a pattern identical to that of histological changes
among all groups (all p < 0.005), whereas markers of anti-apoptosis (Bcl-2) and mitochondrial integrity (mitochondrial
cytochrome-C) as well as left ventricular ejection fraction showed an opposite pattern (all p < 0.001). Protein expressions
of anti-oxidants (HO-1, NQO-1), angiogenesis factors (SDF-1α, CXCR4), and glycogen-like-peptide-1-receptor were
significantly higher inWT-IR-Sita and DPP4D-IR than those in other groups (all p < 0.001).
Conclusion: Abrogation of DPP4 activity protects against myocardial IR injury and preserved heart function.
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unless otherwise stated.of different [1-5]. Despite reperfusion of the ischemic
myocardium during primary percutaneous coronary
intervention (PCI) is essential to minimize myocardial
damage, reperfusion is also well-known for its deleterious
effects [2] due to the generations of oxidative stress,
reactive oxygen species (ROS), and vigorous inflammatory
and immune reactions [1,6-10]. Of particular importance
is that the ROS generated interacts with important pro-
teins, such as ion channels, sarco-endoplasmic reticulum,
calcium-release channels, and myofilament proteins which
are associated with the excitation-contraction coupling.
Alterations of the structures of these proteins can changehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have also shown that ROS are a major contributor to the
opening of the mitochondrial permeability transition pore,
causing the release of cytochrome c and other factors
that can lead to hypercontracture and cell death [11].
This reaction ultimately causes loss of heart contractile
function and alterations in the cardiovascular system
[12,13]. Despite decades of intensive research, ad-
vanced pharmaco-therapeutic strategies, and state-of-
the-art PCI procedure, there is still no effective treat-
ment for myocardial IR injury.
Growing data have shown that glycogen-like peptide-1
(GLP-1) has inhibitory properties against inflammation
and the generations of oxidative stress and ROS [14-17].
Additionally, GLP-1 receptor (GLP-1R) has been identi-
fied in many organs, including the brain, kidney, digestive
organs, and probably also the [14,18,19]. This bioactive
receptor has been shown to be upregulated in the set-
ting of IR injury [14]. Dipeptidyl peptidase-IV (DPP4), a
membrane-anchored ecto-protease, has been identified
as leukocyte antigen CD26. Since GLP-1 is the substrate
of DPP4 enzyme that can cleave circulating GLP-1,
inhibition of DPP4 enzyme activity by sitagliptin, a drug
for the treatment of type II diabetes mellitus and a DPP-
IV inhibitor, has been reported to enhance the circulating
GLP-1 level [14,20-23] which has also been found to be
increased in DPP4-deficient animals and in acute kidney
IR injury [14,22]. Sitagliptin, therefore, may offer cardio-
vascular protection through increasing circulating GLP-1
levels, thereby suppressing inflammation, oxidative stress,
and the formation of atherosclerosis [20]. Accordingly, it
is reasonable to believe that sitagliptin therapy may play a
crucial role in protecting the heart from acute IR injury.
We have recently demonstrated extremely low DPP4
enzyme activity in DPP4-deficient animals [22]. In fact,
DPP4-deficient rats are Fischer 344 rats with mutation
of the DPP4 gene. Hence, it is rational to hypothesize that
DPP4-deficient rats might be less vulnerable to IR-induced
myocardial damage compared to the wide-type Fischer
344. We then further validated this hypothesis by investi-
gating the effect of sitagliptin, a DPP4 inhibitor, on myocar-
dial IRI in an experimental setting.Materials and methods
Ethics
All animal experimental procedures were approved by the
Institute of Animal Care and Use Committee at Chang Gung
Memorial Hospital – Kaohsiung Medical Center (Affidavit
of Approval of Animal Use Protocol No. 2010122405) and
performed in accordance with the Guide for the Care and
Use of Laboratory Animals (NIH publication No. 85–23,
National Academy Press, Washington, DC, USA, revised
1996).Animal grouping and induction of acute myocardial
ischemia-reperfusion injury
Pathogen-free, adult male Fischer 344 (i.e., wide type)
rats (n = 24) weighing about 300-325 g (Charles River
Technology, BioLASCO, Taiwan) were equally categorized
into sham controls (WT-SC, n = 8), acute myocardial IR
injury only (WT-IR, n = 8), and IR + oral sitagliptin
(400 mg/kg) at post-IR 1, 24 and 48 h (WT-IR-Sita, n = 8).
Additionally, adult male DPP4-deficiency rats (DPP4D, i.e.,
DPP4 mutant of Fischer 344; n = 16) weighing about 300-
325 g (Charles River Technology, BioLASCO, Taiwan)
were equally divided into sham control (DPP4D-SC, n = 8)
and DPP4D-IR (n = 8). The dose-titration study which has
been performed in our recent reports [14,22,24] identified
that sitagliptin (400 mg/kg/per day) was the suitable dose
for protecting animals in setting of critical limb ischemia
and acute kidney ischemia-reperfusion injury. Accord-
ingly, the dosage of sitagliptin (400 mg/kg) which was uti-
lized in the present study was basic on our previous
studies [14,22,24]. The time point of ischemia-reperfusion
injury and sitagliptin treatment were basic on our previous
reports with some modification [14,24].
All animals were placed in a supine position under
anesthesia with 2.0% inhalational isoflurane on a warming
pad at 37°C for the IR procedure. Under sterile conditions,
the heart was exposed via a left thoracotomy. IR injury was
induced in WT-IR, WT-IR-Sita, and DPP4D-IR animals by
tightening left coronary artery for 40 minutes 3 mm distal
to the margin of left atrium with a 7–0 prolene suture. Re-
gional myocardial ischemia was verified by observing a
rapid color change from pink to dull red over the anterior
surface of the left ventricle and rapid development of akin-
esia and dilatation over the affected region. Rats receiving
thoracotomy only without ischemia induction served as
sham controls. The knot was then relieved after 40-minute
ischemia, followed by 72 h reperfusion. The rats were sacri-
ficed at 72 h after IR procedure, and hearts were harvested
for individual study. The blood was collected from each
animal for measuring the circulating level of GLP-1 by
ELISA method using a commercialized kit. The dosages of
sitagliptin to be utilized in this experiment were based on
our recent report [14,16] with some modifications.
Functional assessment by echocardiography
Transthoracic echocardiography was performed in each
group prior to and on day 3 after myocardial IR induction.
The procedure was performed by an animal cardiologist
blind to the experimental design using an ultrasound
machine (Vevo 2100, Visualsonics). M-mode standard
two-dimensional (2D) left parasternal-long axis echo-
cardiographic examination was conducted. Left ventri-
cular internal dimensions [end-systolic diameter (ESD)
and end-diastolic diameter (EDD)] were measured at
mitral valve and papillary levels of left ventricle, according
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method using at least three consecutive cardiac cycles. Left
ventricular ejection fraction (LVEF) was calculated as
follows: LVEF (%) = [(LVEDD3-LVEDS3)/LVEDD3] × 100%.
Procedure and protocol for measurement of reactive
oxygen species (ROS)
For determining the fluorescent intensity of ROS in
myocardium, four additional animals were utilized in each
study group. The protocol and detailed procedure of this
test were based on our previous report [25]. By the end of
study period (i.e., at 72 h after IR procedure), 2′,7′-
dichlorodihydrofluorescin diacetate (H2DCFDA, Molecu-
lar Probes) was dissolved in DMSO at a concentration of
25 mg/mL. After being diluted with 50% ethanol to a
final concentration of 2.5 mg/mL, it was administered
intravenously at a dose of 6 μg/gm body weight to each
animal. The rats were sacrificed 30 minutes following
H2DCFDA administration.
The hearts were excised and sectioned at a level between
the ligation and the apex. Totally three 2 mm-thick sections
were obtained from each heart. All sections were examined
under fluorescent microscope under a magnification of
100×. Both captured fluorescence and gray photos were
assessed by using DP controller 2.1.1.183 (Olympus). Gray
photos for measuring the fluorescence intensity were proc-
essed by using Image J 1.37v (National Institutes of Health,
USA). Three gray photos from each section were randomly
obtained, giving a total of nine photos for each animal. As
compared with the area of increased fluorescence intensity
(IFI), the baseline fluorescence intensity (BFI) [arbitrary
unit/400 × high-power field (HPF)] was defined as that in
myocardium without H2DCFDA. Six BFI areas were
measured from each gray photo, from which three BFI
areas were randomly chosen. The mean IFI and mean
BFI were then calculated. The ratio of IFI to the BFI was
determined as the relative fluorescence intensity.
Western blot analysis of heart tissue
The procedure and protocol for Western blot analysis
were based on our recent reports [14,22]. Briefly, equal
amounts (50 μg) of protein extracts were loaded and
separated by SDS-PAGE using acrylamide gradients.
After electrophoresis, the separated proteins were trans-
ferred electrophoretically to a polyvinylidene difluoride
(PVDF) membrane (Amersham Biosciences). Nonspe-
cific sites were blocked by incubation of the membrane
in blocking buffer [5% nonfat dry milk in T-TBS (TBS
containing 0.05% Tween 20)] overnight. The membranes
were incubated with the indicated primary antibodies [Bax
(1: 1000, Abcam), cleaved poly (ADP-ribose) polymerase
(PARP) (1:1000, Cell Signaling), caspase 3 (1: 1000, Cell
Signaling), Bcl-2 (1:200, Abcam), (ICAM)-1 (1: 2000,
Abcam), polyclonal antibodies against tumor necroticfactor (TNF)-α (1: 1000, Cell Signaling), nuclear factor
(NF)-κB (1: 250, Abcam), MMP-9 (1:3000, Abcam), CXCR4
(1:1000, Abcam), stromal cell-derived factor (SDF)-1α
(1:1000, Cell Signaling), NAD(P)H quinone oxidoreduc-
tase (NQO) 1 (1: 1000, Abcam), heme oxygense (HO)-1
(1: 250, Abcam), NADPH oxidase (NOX)-1 (1:1500,
Sigma), NOX-2 (1:500, Sigma), cytosolic cytochrome C
(1:2000, BD), mitochondrial cytochrome C (1:2000,
BD), and GLP-1R (1:1000, abcam)] for 1 hour at room
temperature. Horseradish peroxidase-conjugated anti-
rabbit immunoglobulin IgG (1:2000, Cell Signaling)
was used as a secondary antibody for one-hour incuba-
tion at room temperature. The washing procedure was
repeated eight times within one hour. Immunoreactive
bands were visualized by enhanced chemiluminescence
(ECL; Amersham Biosciences) and exposed to Biomax
L film (Kodak). For the purpose of quantification, ECL
signals were digitized using Labwork software (UVP).
Oxidative stress reaction in LV myocardium
The procedure and protocol for assessing the protein ex-
pression of oxidative stress have been described in details
in our previous reports [26,27]. The Oxyblot Oxidized Pro-
tein Detection Kit was purchased from Chemicon (S7150).
DNPH derivatization was carried out on 6 μg of protein
for 15 minutes according to the manufacturer’s instruc-
tions. One-dimensional electrophoresis was carried out on
12% SDS/polyacrylamide gel after DNPH derivatization.
Proteins were transferred to nitrocellulose membranes
which were then incubated in the primary antibody solu-
tion (anti-DNP 1: 150) for 2 hours, followed by incubation
in secondary antibody solution (1:300) for 1 hour at room
temperature. The washing procedure was repeated eight
times within 40 minutes. Immunoreactive bands were visu-
alized by enhanced chemiluminescence (ECL; Amersham
Biosciences) which was then exposed to Biomax L film
(Kodak). For quantification, ECL signals were digitized
using Labwork software (UVP). For oxyblot protein ana-
lysis, a standard control was loaded on each gel.
Immunofluorescent (IF) and immunohistochemical (IHC)
staining
IF staining was performed for the examinations of CD68+
and γ-H2AX cells in LV myocardium using respective
primary antibodies based on our recent study [14,22,26].
Moreover, IHC staining was performed for examinations
of CD14 and CD40 using respective primary antibodies as
described [14,22,26]. Irrelevant antibodies were used as
controls in the current study.
Histological quantification of myocardial fibrosis/infarct
and collagen deposition
The procedure and protocol was described in details in
our previous report [26]. Briefly, hematoxylin and eosin
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identifying the infarct area and fibrosis of LV myocar-
dium, respectively. Three serial sections of LV myocar-
dium in each animal at the same levels were prepared at
4 μm thickness by Cryostat (Leica CM3050S). The inte-
grated area (μm2) of infarct area and fibrosis on each
section were calculated using the Image Tool 3 (IT3)
image analysis software (University of Texas, Health
Science Center, San Antonio, UTHSCSA; Image Tool for
Windows, Version 3.0, USA). Three randomly selected
high-power fields (HPFs) (100 ×) were analyzed in each
section. After determining the number of pixels in each
infarct and fibrotic area per HPF, the numbers of pixels
obtained from three HPFs were summated. The procedure
was repeated in two other section for each animal. The
mean pixel number per HPF for each animal was then
determined by summating all pixel numbers and divid-
ing by 9. The mean integrated area (μm2) of fibrosis in
LV myocardium per HPF was obtained using a conver-
sion factor of 19.24 (1 μm2 represented 19.24 pixels).
To analyze the extent of collagen synthesis and depos-
ition, cardiac paraffin sections (6 μm) were stained with
picrosirius red (1% Sirius red in saturated picric acid
solution) for one hour at room temperature using stand-
ard methods. The sections were then washed twice with
0.5% acetic acid. The water was physically removed from
the slides by vigorous shaking. After dehydration in 100%
ethanol thrice, the sections were cleaned with xylene and
mounted in a resinous medium. High power fields (×100)
of each section were used to identify Sirius red-positive area
on each section. Analytical sections of collagen deposition
area in LV myocardium were identical to the description






Serum GLP-1 level (pg/ml)* 32.6 ± 2.3a 39.1 ± 3.1b
Baseline echocardiography
LVEDd (cm) 6.8 ± 0.21 6.7 ± 0.21
LVESd (cm) 3.4 ± 0.20 3.5 ± 0.18
LEVF (%) 79.0 ± 1.8 79.0 ± 2.10
Day 3 echocardiography*
LVEDd (cm) 6.5 ± 0.24a 6.9 ± 0.37b
LVESd (cm) 3.3 ± 0.18a 5.7 ± 0.24b
LVEF (%) 81.0 ± 1.60a 34.0 ± 4.2b
Data are expressed as mean ± SD or %.
Group 1 = sham control [Wide type (WT)]; Group 2 =WT + ischemia-reperfusion (IR);
Group 5 =WT + IR + sitagliptin.
LVEDd = left ventricular end-diastolic dimension; LVESd = left ventricular end systoli
*indicates the blood sampling was performed at 72 h after the IR procedure.
†indicates by one-way ANOVA. Different letters (a, b, c) being used for group comp
Bonferroni’s multiple comparison procedure.Statistical analysis
Quantitative data are expressed as means ± SD. Statistical
analysis was adequately performed by ANOVA followed
by Bonferroni multiple-comparison post hoc test. SAS
statistical software for Windows version 8.2 (SAS institute,
Cary, NC) was utilized. A probability value <0.05 was
considered statistically significant.
Results
The circulating level of GLP-1 at 72 h after IR injury
By day 3 after IR injury, the circulating level of GLP-1
was highest in DPP4D + IR group and lowest in WT-SC,
significantly higher in WT-IR-Sita group than that in
WT-IR, but it exhibited no difference between WT-IR-
Sita and DPP4D-SC groups, or between DPP4D-SC and
WT-IR groups (Table 1). These findings suggest that
DPP4D, IR injury, and sitagliptin treatment enhance the
circulating level of GLP-1.
Heart function prior to and at 72 h after IR injury
Table 1 showed the results of echocardiography findings.
Prior to the IR procedure (i.e. day 0), the left ventricular
ejection fraction (LVEF), left ventricular end-diastolic
dimension (LVEDd) and left ventricular end-systolic
dimension (LVESd) did not differ among the five groups.
However, at 72 h after reperfusion, LVEF was signifi-
cantly reduced, whereas LVEDd and LVESd were signifi-
cantly increased in the WT-IR group as compared with
the other groups. Additionally, LVEF was significantly
reduced whereas LVEDd and LVESd were significantly
increased in WT-IR-Sita and DPP4D-IR groups as
compared to those of WT-SC and DPP4D-SC groups,








42.1 ± 4.7b,c 45.2 ± 2.9c 48.2 ± 4.1d,c <0.0001
6.4 ± 0.23 6.5 ± 0.24 6.5 ± 0.30 0.448
3.4 ± 0.21 3.5 ± 0.20 3.4 ± 0.22 0.867
76.2 ± 3.70 77.0 ± 2.30 78.1 ± 2.80 0.662
6.4 ± 0.38a 6.8 ± 0.34b 6.7 ± 0.28b 0.035
3.4 ± 0.22a 4.3 ± 0.27c 4.2 ± 0.21c <0.001
78.0 ± 3.40a 67.0 ± 3.70c 67 ± 3.30c <0.001
Group 3 = DDP4-deficiency (DDP4D); Group 4 = DDP4D + IR;
c dimension; LVEF = left ventricular ejection fraction.
arison, showing significant difference (<0.05) among different groups by
Figure 1 (See legend on next page.)
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Figure 1 Reactive oxygen species (ROS) generation in heart of live rats and pathological findings at 72 h after ischemia-reperfusion (IR)
procedure. A to E) Immunofluorescent microscopic findings (400×) of 2′,7′-dichlorodihydrofluorescin diacetate (H2DCFDA) stain for identifying
the ROS generation in left ventricular (LV) myocardium. F) Analytic results of fluorescent intensity, p < 0.0001, * vs. other groups with different
symbols (*, †, ‡). Scale bars in right lower corner represent 20 μm. G to K) Microscopic findings (100×) of H&E stain for identifying the infarct
area in LV myocardium. L) Analytic results of infarct area, p < 0.0001, * vs. other groups with different symbols (*, †, ‡). Scale bars in right lower
corner represent 100 μm. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test
(n = 8). Symbols (*, †, ‡) indicate significance (at 0.05 level). WT-SC = wide type sham control; WT-IR = wide type + ischemia reperfusion (IR);
DDP4D-SC = dipeptidyl peptidase-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D + IR; WT-IR-Sita = wide type + IR + sitagliptin. HPF = high-power
field. M and N) The Western blot results showed that the protein expression of circulating CD26, an indicator of DDP-4 activity, was remarkably
suppressed in Fischer 344 rat with (N) than in without (M) sitagliptin treatment. O and P) The Western blot results showed that the protein
expression of circulating CD26 in DDP-4 deficient rat (P) was lost as compared with that of circulating CD26 in Fischer 344 rat (O).
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the latter two groups at 72 h after reperfusion. These find-
ings suggest that DPP4D and sitagliptin treatment pre-
served LV function and inhibited LV remodeling in the
setting of IR-induced myocardial damage.
ROS generation and histopathological findings at 72 h
after IR procedure
To assess the role of DPP4D and sitagliptin therapy in
ROS expression in IR region of LV myocardium, the
fluorescent intensity was quantified using H2DCFDA
labeling of the myocardium as described in our previ-
ous study [25]. As expected, the relative fluorescence
intensity was significantly increased in WT-IR than in
other groups, significantly elevated in WT-IR-Sita and
DPP4D-IR groups than in WT-SC and DPP4D-SC groups,
but it showed no difference between the former two
groups or between the latter two groups (Figure 1).
H&E staining demonstrated that the infarct area of left
ventricle was largest in the WT-IR animals, significantly
higher in WT-IR-Sita and DPP4D-IR groups than that in
WT-SC and DPP4D-SC groups. However, the infarct area
was not only similar between the former two groups,
but it was also similar between the latter two groups
(Figure 1). Additionally, Sirius-red staining demonstrated
that the collagen deposition area in LV myocardium was
identical to the result of H&E staining among the five
groups of animals (Figure 2). Furthermore, Masson's
trichrome staining showed that the fibrosis area in LV
myocardium was identical to the finding of H&E stain-
ing among the five groups (Figure 2). These four histo-
pathological findings imply that DPP4D and sitagliptin
treatment reduced ROS production and infarct size in
the setting of IR-induced myocardial injury.
Identifications of DNA damage marker and inflammatory
cells in infarct region using IHC and IF stains at 72 h after
reperfusion
The IF staining demonstrated that the expression of
γ-H2AX-positive cells, an index of DNA damage, was
significantly higher in WT-IR group than in other groups,
and significantly higher in WT-IR-Sita and DPP4D-IRgroups than in WT-SC and DPP4D-SC groups, but it
showed no difference between the former two groups or
between the later two groups (Figure 3). In addition, IF
staining of LV infarct myocardium demonstrated that
the pattern of changes in the number of CD68+ cells,
another inflammation biomarker, was similar to that
of γ-H2AX+ cells among the five groups (Figure 3).
Furthermore, the IHC staining showed that the numbers of
CD14+ and CD40+ cells in LV infarct myocardium, two in-
dicators of inflammation, was identical to that of number of
CD68+ cells among the five groups (Figure 4). These IHC/
IF microscopic findings suggest that DPP4D and sitagliptin
treatment ameliorated DNA damage and inflammatory cell
infiltration in the ischemic/infarct areas.
Protein expressions of inflammatory biomarkers at 72 h
after reperfusion
The protein expressions of TNF-α (Figure 5-A), NF-κB
(Figure 5-B), MMP-9 (Figure 5-C), and ICAM-1 (Figure
5-D), four indices of inflammation, were highest in the
WT-IR group, significantly higher in the WT-IR-Sita
and DPP4D-IR groups than those in the WT-SC and
DPP4D-SC groups, but no significant difference was noted
between the former two groups or between the latter two
groups. These findings imply that DPP4D and sitagliptin
treatment attenuated inflammation at the molecular-
cellular level.
Myocardial ROS production, and protein expressions of
ROS and oxidative stress at 72 h after reperfusion
The protein expressions of NOX-1 (Figure 6-A) and
NOX-2 (Figure 6-B), two ROS biomarkers, were highest in
the WT-IR group, significantly higher in the WT-IR-Sita
and DPP4D-IR groups than in the WT-SC and DPP4D-SC
groups, but there was no significant difference between
the former two groups or between the latter two groups.
Consistently, the oxidized protein, an index of oxidative
stress, showed an identical pattern compared with the
protein expressions of ROS among the five groups
(Figure 6-C). These findings indicate that DPP4D and
sitagliptin therapy suppressed the generation of ROS
and alleviated the oxidative stress.
Figure 2 Histopathological findings of left ventricular (LV) myocardium at 72 h after IR procedure. A to E) Microscopic findings (100×)
of Sirius red staining for identifying the collagen deposition in infarct area among five groups. F) Analytic results of collagen deposition,
p < 0.0001, * vs. other groups with different symbols (*, †, ‡). Scale bars in right lower corner represent 100 μm. G to K) Microscopic findings
(100×) of Masson's Trichrome staining for identifying the fibrotic area in LV myocardium. L) Analytic results of infarct area, p < 0.0001, * vs. other groups
with different symbols (*, †, ‡). Scale bars in right lower corner represent 100 μm. All statistical analyses were performed by one-way ANOVA, followed
by Bonferroni multiple comparison post hoc test (n = 8). Symbols (*, †, ‡) indicate significance (at 0.05 level). WT-SC = wide type sham control;
WT-IR = wide type + ischemia reperfusion (IR); DDP4D-SC = dipeptidyl peptidase-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D + IR;
WT-IR-Sita = wide type + IR + sitagliptin. HPF = high-power field.
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Figure 3 Immunofluorescent (IF) stains of DNA damaged marker (γ-H2AX) and inflammatory cell (CD68+) infiltration in LV myocardium
at 72 h after IR procedure. A to E) IF microscopic findings (400×) of γ-H2AX+ cells (white arrows) in non-infarct area of LV myocardium. F)
Comparison of number of γ-H2AX+ cells in non-infarct area among the five groups. p < 0.0001, * vs. other groups with different symbols (*, †, ‡). Scale
bars in right lower corner represent 20 μm. G to K) IF Microscopic findings (200×) of CD68+ cells (white arrows) in infarct area. L) Comparison
of number of CD68+ cells among the five groups. p < 0.0001, * vs. other groups with different symbols (*, †, ‡). Scale bars in right lower corner
represent 50 μm. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n = 8).
Symbols (*, †, ‡) indicate significance (at 0.05 level). WT-SC = wide type sham control; WT-IR = wide type + ischemia reperfusion (IR); DDP4D-SC
= dipeptidyl peptidase-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D + IR; WT-IR-Sita = wide type + IR + sitagliptin.
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Figure 4 Immunohistochemical (IHC) stains of inflammatory cell infiltrations in LV myocardium at 72 h after IR procedure. A to E)
Microscopic findings (400×) of IHC staining for identifying CD14+ cells (brown color) (yellow arrows) in infarct area. F) Comparison of number of
CD14+ cells among the five groups. p < 0.0001, * vs. other groups with different symbols (*, †, ‡). Scale bars in right lower corner represent 20 μm.
G to K) Microscopic findings (400×) of IHC stain for identifying CD40+ cells (brown color) (yellow arrows) in infarct area. L) Comparison of number of
CD40+ cells among the five groups. p < 0.0001, * vs. other groups with different symbols (*, †, ‡). Scale bars in right lower corner represent 20 μm. All
statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n = 8). Symbols (*, †, ‡)
indicate significance (at 0.05 level). WT-SC = wide type sham control; WT-IR = wide type + ischemia reperfusion (IR); DDP4D-SC = dipeptidyl
peptidase-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D + IR; WT-IR-Sita = wide type + IR + sitagliptin.
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Figure 5 Protein expressions of inflammatory biomarkers in LV myocardium at 72 h after IR procedure. A) Protein expression of tumor
necrosis factor (TNF)-α in LV myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡). B) Protein expression of nuclear factor
(NF)-κB in LV myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡). C) Protein expression of matrix metalloproteinase (MMP)-9
in LV myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡). D) Protein expression of intercellular adhesion molecule (ICAM)-1.
p < 0.001, * vs. other groups with different symbols (*, †, ‡). All statistical analyses were performed by one-way ANOVA, followed by Bonferroni
multiple comparison post hoc test (n = 8). Symbols (*, †, ‡) indicate significance (at 0.05 level). WT-SC = wide type sham control; WT-IR = wide
type + ischemia reperfusion (IR); DDP4D-SC = dipeptidyl peptidase-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D + IR; WT-IR-Sita =wide type + IR +
sitagliptin.
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Figure 6 Protein expressions of reactive oxygen species (ROS) and oxidative stress in LV myocardium at 72 h after IR procedure. A)
Protein expression of NOX-1 in LV myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡). B) Protein expression of NOX-2 in LV
myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡). C) Protein expression of oxidative index (protein carbonyls) in LV myocardium.
p < 0.0001, * vs. other groups with different symbols (*, †, ‡). (Note: right and left lanes shown on the upper panel represent control oxidized molecular
protein and standard and protein molecular weight marker, respectively). DNP = 1–3 dinitrophenylhydrazone. All statistical analyses were performed by
one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n = 8). Symbols (*, †, ‡) indicate significance (at 0.05 level). WT-SC =wide
type sham control; WT-IR =wide type + ischemia reperfusion; DDP4D-SC = dipeptidyl peptidase-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D +
ischemia reperfusion; WT-IR-Sita =wide type + ischemia reperfusion + sitagliptin.
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mitochondrial damage biomarkers at 72 h after reperfusion
The protein expressions of mitochondrial Bax (Figure 7-A)
and cleaved (i.e., active form) caspase 3 (Figure 7-B), and
PARP (Figure 7-C), three indicators of apoptosis, weresignificantly higher in WT-IR group than in other
groups, significantly higher in WT-IR-Sita and DPP4D-IR
groups than in WT-SC and DPP4D-SC groups, but these
parameters exhibited no difference between the former two
groups or between the latter two groups. Additionally, the
Figure 7 Protein expressions of apoptotic, anti-apoptotic and mitochondrial damage biomarkers in LV myocardium at 72 h after IR
procedure. A) Protein expression of mitochondrial Bax in LV myocardium. p < 0.008, * vs. other groups with different symbols (*, †, ‡). B) Protein
expression of cleaved caspase (Csp)-3 in LV myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡). C) Protein expression of
cleaved poly (ADP-ribose) polymerase (PARP) in LV myocardium. p < 0.01, * vs. other groups with different symbols (*, †, ‡). D) Protein expression
of cytosolic cytochrome C (Cyto-Cyt C) in LV myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡). E) Protein expression of
Bcl-2 in LV myocardium. p < 0.01, * vs. other groups with different symbols (*, †, ‡). F) Protein expression of mitochondrial cytochrome C (Mito-Cyt C) in
LV. p < 0.001, * vs. other groups with different symbols (*, †, ‡). All statistical analyses were performed by one-way ANOVA, followed by Bonferroni
multiple comparison post hoc test (n = 8). Symbols (*, †, ‡) indicate significance (at 0.05 level). WT-SC = wide type sham control; WT-IR = wide
type + ischemia reperfusion; DDP4D-SC = dipeptidyl peptidase-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D + ischemia reperfusion;
WT-IR-Sita = wide type + ischemia reperfusion + sitagliptin.
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an index of mitochondrial damage, showed an identical pat-
tern compared to that of apoptotic biomarkers among the
five groups. On the other hand, the protein expressions of
Bcl-2 (Figure 7-E), an indicator of anti-apoptosis, and mito-
chondrial cytochrome C (Figure 7-F), an index of mito-
chondrial preservation, showed an opposite pattern
compared to those of apoptotic biomarkers. These findings
indicate that DPP4D and sitagliptin treatment significantly
reduced cellular apoptosis and mitochondrial damage.The protein expressions of GLP-1R and anti-oxidants at
72 h after IR procedure
The protein expression of GLP-1R was lowest in the
WT-SC group, significantly lower in the WT-IR and
DPP4D-SC groups than that in the WT-IR-Sita and
DPP4D-IR groups, but there is no notable difference be-
tween the former two groups or the latter two groups
(Figure 8-A). Moreover, the protein expression of HO-1,
an indicator of anti-oxidant, was also lowest in the
WT-SC group but highest in the WT-IR-Sita group,
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than that in the DPP4D-IR animals, but it showed
no difference between the WT-IR and DPP4D groups
(Figure 8-B). Furthermore, the protein expression of
NQO 1, another indicator of anti-oxidant, was lowest
in the WT-SC group but highest in the WT-IR-Sita and
DPP4D-IR groups, significantly lower in the WT-IR
group than that in the DPP4D group, but this parameter
did not differ between the WT-IR-Sita and DPP4D-IR
groups (Figure 8-C). These findings imply that DPP4D
and sitagliptin treatment offered anti-oxidative thera-
peutic effects.
The expressions of angiogenesis factors and cardiac stem
cells at 72 h after IR procedure
The protein expressions of SDF-1α (Figure 9-A) and
CXCR4 (Figure 9-B), two angiogenesis factors, were
significantly lower in the WT-SC and DPP4D-SC groups
than in other groups, significantly lower in WT-IR group
than in that of DPP4D-IR and WT-IR-Sita groups, but is
was no difference in the later two groups. Additionally, the
numbers of c-kit + (Figure 9-C) and Sca-1+ (Figure 9-D)
cells, two indicators of cardiac progenitor cells, were lowest
in WT-SC group and highest in DPP4D-IR and WT-IR-Sita
groups, and significantly higher in WT-IR group than in
DPP4D-SC group. These findings may suggest that acute
IR injury induced an elevation in intrinsic angiogenesis
factors and proliferation of cardiac progenitor cells toFigure 8 Protein expressions of GLP-1 and antioxidants in LV myocardiu
peptide-1 (GLP-1) in LV myocardium. p < 0.001, * vs. other groups with differe
myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡, §). C)
myocardium. p < 0.001, * vs. other groups with different symbols (*, †, ‡, §
by Bonferroni multiple comparison post hoc test (n = 8). Symbols (*, †, ‡)
WT-IR = wide type + ischemia reperfusion; DDP4D-SC = dipeptidyl peptida
reperfusion; WT-IR-Sita = wide type + ischemia reperfusion + sitagliptin.protect myocardium against ischemia and that deletion
of DPP4 enzyme activity might offer the most effective
protection against IR-induced myocardial damage.Discussion
This study, which utilized DPP4-deficiency rats to
clarify the therapeutic impact of sitagliptin, an oral
hypoglycemic agent with distinctive property of inhibit-
ing DPP4 enzyme activity, on the heart against IR injury
in a rodent model, yielded several striking implications.
First, not only were the size of LV infarct area and colla-
gen deposition in infarct area significantly reduced, but
LV function was also notably preserved in the WT-IR-
Sita group than that in the WT-IR group. Second, the
expressions of inflammatory, oxidative-stress, ROS, apop-
totic, and myocardial damage biomarkers in infarct myo-
cardium were remarkably reduced in the WT-IR-Sita
animals than those in the WT-IR group. Consistently, the
pattern of changes in these parameters in the DPP4D-IR
group was identical to that in the WT-IR-Sita group.
Third, the circulating GLP-1 levels and the expressions of
anti-oxidants and GLP-1R in infarct myocardium were
found to be markedly higher in the WT-IR-Sita group
than that in the WT-IR group. In this regard, the changes
of these biomarkers in DPP4D-IR animals showed a
similar pattern compared to that in their WT-IR-Sita
counterparts.m at 72 h after IR procedure. A) Protein expression of glycogen-like
nt symbols (*, †, ‡). B) Protein expression heme oxygense (HO)-1 in LV
Protein expression of NAD(P)H quinone oxidoreductase (NQO) 1 in LV
). All statistical analyses were performed by one-way ANOVA, followed
indicate significance (at 0.05 level). WT-SC = wide type sham control;
se-IV (DPP4) deficiency sham control; DDP4D-IR = DDP4D + ischemia
Figure 9 (See legend on next page.)
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Figure 9 Expressions of angiogenesis and cardiac progenitor cell biomarkers in LV myocardium at 72 h after IR procedure. A) Protein
expression of stromal cell-derived factor (SDF)-1α in LV myocardium. p < 0.01, * vs. other groups with different symbols (*, †, ‡). B) Protein expression of
CXCR4 in LV myocardium. p < 0.01, * vs. other groups with different symbols (*, †, ‡). C) Expression of c-kit + cells in LV myocardium. <0.0001, * vs. other
groups with different symbols (*, †, ‡, §). D) Expression of Sca-1+ cells in LV myocardium. <0.0001, * vs. other groups with different symbols (*, †, ‡, §).
All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n = 8). Symbols (*, †, ‡) indicate
significance (at 0.05 level). WT-SC = wide type sham control; WT-IR = wide type + ischemia reperfusion; DDP4D-SC = dipeptidyl peptidase-IV
(DPP4) deficiency sham control; DDP4D-IR = DDP4D + ischemia reperfusion; WT-IR-Sita = wide type + ischemia reperfusion + sitagliptin.
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suppression of LV remodeling, and preservation of LV
function after sitagliptin treatment ― role of inhibiting
DPP4 enzyme activity
Although several previous studies have shown that
DPP4 inhibitors are capable of offering cardiovascular
protection and preserving cardiac functions from myo-
cardial ischemia [20,24,26-30], the precise mechanisms
involved have not been extensively investigated. The
most important findings in the present study is that, as
compared with WT-SC, the infarct size, the fibrotic zone
and collagen-deposited area of infarct myocardium and
LV remodeling were substantially increased, whereas the
cardiac function was notably reduced in the WT-IR
animals and were remarkably restored in the WT-IR-Sita
animals. To further elucidate whether the observation of
cardiac protection offered by sitagliptin was through the
inhibition of DPP4 enzyme activity, the extent of IR
injury in DPP4-deficiency rats was investigated. As
expected, the cardiac protective effects (i.e., reduction of
infarct size, fibrotic area collagen-deposited region, and
LV remodeling as well as preservation of cardiac func-
tion) in DPP4D-IR animals were found to be identical to
that in the WT-IR-Sita group. Our results are consistent
with those of previous studies [27,29] that demonstrated
cardiac protection against ischemia-related myocardial
injury through genetic deletion of DPP4.
GLP-1 is the substrate of DPP4 that has been revealed
to be capable of catalyzing the release of dipeptides from
the N-terminus of GLP-1 which contains Pro or Ala in
the third amino acid position [30]. Additionally, it is well
recognized that sitagliptin can increase circulating GLP-1
levels via inhibiting DPP4 enzyme activity [14,20,21,23].
Accordingly, to elucidate whether the protective effect of
sitagliptin against cardiac IR injury was through increasing
the circulating level of GLP-1 and enhancing GLP-1R
expression in LV myocardium, the levels of these two
biomarkers were determined in the present study. As
expected, the circulating level of GLP-1 and the protein
expression of GLP-1R in myocardium were significantly
increased in the WT-IR groups and further significantly
increased in the WT-IR-Sita animals than in WT-SC
animals. Intriguingly, in DPP4D animals (i.e., DPP4
enzyme activity abrogated), the circulating level of GLP-1
was significantly higher as compared with that in WT-SCanimals. Of particular importance is that the circulating
GLP-1 level and protein expression of GLP-1R in LV myo-
cardium were significantly increased in the DPP4D-IR
group than those in the DPP4D-SC group. However, it
showed no difference between the WT-IR-Sita and
DPP4D-IR animals. These findings not only suggest that
IR injury could induce intrinsic protective mechanism,
but also support that augmentation of circulating GLP-1
level and GLP-1R expression in ischemic organ through
sitagliptin treatment or DPP4 genetic deletion is one of
the mechanisms involved in preserving heart function
in the setting of IR injury. Our recent study [14] has
shown that pharmacological inhibition of DPP4 by sita-
gliptin protected the kidney from IR injury mainly through
increasing the endogenous level of GLP-1. In this way,
our present finding is consistent with that of our recent
report [14]. The proposed mechanisms by which through
genetic deletion of DPP4 or sitagliptin therapy preserved
heart function in a rodent model have been summarized
in Figure 10.
Up-regulating down-stream signalings of inflammatory
reaction and the generations of oxidative stress and ROS
in ischemia-reperfusion injury ― role of GLP-1 receptor
pathway
Our previous experimental [14,24,26,31] have clearly shown
that inflammation, ROS (i.e., oxygen free radicals), and
oxidative stress, which are deleterious contributors to
mitochondrial damage and cellular apoptosis, fibrosis
and death as well as the propagation of organ dysfunc-
tion, were markedly up-regulated in the setting of ische-
mic organ dysfunction. The findings are consistent with
those of the present study that demonstrated significant
up-regulations in inflammation, ROS and oxidative stress,
as well as apoptosis in the WT-IR animals compared with
those in the WT-SC and DPP4D-SC animals. One distinct-
ive finding is that these parameters were substantially
down-regulated and the anti-apoptotic markers were
notably up-regulated in the WT-IR-Sita animals. This is
also in concert with the finding of our recent study that
demonstrated remarkable inhibition of the expressions
of inflammation, ROS, and oxidative stress in the set-
tings of acute kidney injury and critical limb ischemia
after sitagliptin treatment [14,24]. Another intriguing
finding is that there was no difference in these parameters
Figure 10 Proposed mechanisms underlying the genetic deletion of DPP4 or therapeutic effect of sitagliptin on protecting heart from
acute ischemia-reperfusion injury. IR = ischemia-reperfusion; GLP-1 = glycogen-like peptide-1; DDP4 = dipeptidyl peptidase 4; HO-1 = heme
oxygense-1; NQO 1 = NAD(P)H quinone oxidoreductase 1; c-PARP = cleaved poly (ADP-ribose) polymerase; c-Csp 3 = caspase 3; Cyto-Cyt C = cytosolic
cytochrome C; TNF-α = tumor necrosis factor alpha; MMP-9 =matrix metalloproteinase 9; NF-κB = nuclear factor κB; ICAM-1 = intercellular adhesion
molecule 1; SDF-1 = stromal cell-derived factor 1; LVEDd = left ventricular end diastolic dimension; LVESd = left ventricular systolic dimension; LVEF = left
ventricular ejection fraction.
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fore, the findings suggest that sitagliptin suppressed in-
flammatory reaction, oxidative stress (i.e., the generations
of ROS), and cellular apoptosis through the up-regulation
of circulating GLP-1 and the interaction between GLP-1
and GLP-1R (i.e., GLP-1R pathway) on cardiomyocytes in
the setting of cardiac IR injury. Accordingly, our findings
also strengthen those of previous studies that demon-
strated cardiovascular protective effect of DPP4 inhibitor/
DPP4-deficiency through attenuating the productions of
ROS [16] and oxidative stress [32].
Inhibiting damaging effect of ROS and oxidative stress on
myocardium through GLP-1-GLP-1R interacting pathway―
Up-regulation of anti-oxidant production
Anti-oxidants have been fully accepted as scavengers of
ROS that alleviate oxidative stress at molecular-cellular
level, especially in ischemia-related organ damage. Our re-
cent study has shown that both sitagliptin and extendin-4
(i.e., an analogs of GLP-1) treatment offered effectivecytoprotection through up-regulating the production of
anti-oxidants and reducing the tissue levels of ROS in
acute kidney IR injury [14]. A principal finding in the
present study is that the protein expressions of antioxi-
dants (HO-1, NQO 1) was markedly higher in WT-IR and
DDF4D-SC animals than in WT-SC animals and the levels
of these biomarkers were further markedly elevated in
the WT-IR-Sita and the DPP4D-IR animals. The find-
ings of high-level anti-oxidant production in DPP4D-IR
animals imply that sitagliptin offers cardioprotective
effect via enhancing the generation of anti-oxidants that
alleviate the deleterious effect of ROS/oxidative stress
on cardiomyocytes.
Enhanced angiogenesis in infarct myocardium ― role of
sitagliptin and deletion of DPP4 enzyme activity
A previous study has demonstrated that inhibition of
DPP4 activity by enalapril enhanced the mobilization of
endothelial progenitor cell (EPC) from bone marrow to
circulation in the setting of critical limb ischemia [33].
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tin therapy augmented EPC mobilization from bone
marrow to circulation and enhanced angiogenesis in
ischemic regions [14,24]. An important finding in the
current study is that, as compared with WT-SC and
DPP4D-SC animals, the protein expression of angiogen-
esis factors (i.e., CXCR4 and SDF-1α) and the number
of cardiac stem cells (i.e., c-kit and Sca-1) in infarct
area were significantly higher in WT-IR animals. These
findings may suggest that the ischemic stimulus trig-
gered an intrinsic response in tissue/organ for self-
protection. Intriguingly, these biomarkers were found to
be notably higher in WT-IR-Sita than in WT-IR group.
These findings corroborate those of our recent studies
[14,24]. Of importance is that the expressions of these
biomarkers in infarct LV did not differ between the
WT-IR-Sita and DPP4D-IR animals. Our findings, in
addition to supporting those of previous studies [33],
also highlight that enhancement of angiogenesis and
cardiac stem cell in ischemic area is mainly through the
abrogating DPP4 activity. Therefore, our findings sug-
gest that sitagliptin therapy and deletion of DPP4 may
offer benefit in preserving cardiac function through
restoring blood flow and regeneration of lost myocar-
dium by cardiac stem cells.Study limitations
This study has limitations. First, this study did not inves-
tigate the impact of inhibition of DPP4 activity on long-
term outcome of the animals after IR procedure. Second,
although the dosage of sitagliptin to be utilized was based
on our previous report [14], this study did not investigate
which was the optimal sitagliptin dosage for the best myo-
cardial protecting in the present IR setting based on pilot
experiments.
In conclusion, inhibition of DPP4 activity protected the
heart against IR injury and left ventricular remodeling and
preserved heart function through down-regulating inflam-
mation, oxidative stress, ROS generation, and cell apop-
tosis as well as up-regulating antioxidant production and
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